HER2.taNK - NantKwest

Drug Profile

HER2.taNK - NantKwest

Alternative Names: CAR-natural killer cell therapy - NantKwest; HER2.tank; HER2taNK; NK-92/5.28.z; taNK cells - NantKwest; Target-activated natural killer cells - NantKwest

Latest Information Update: 17 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NantKwest
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Cell death stimulants; Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioblastoma

Most Recent Events

  • 01 Dec 2017 Phase-I clinical trials in Glioblastoma (Recurrent, Late-stage disease, Second-line therapy or greater) in Germany (Intracranial injection) (DRKS00013333) (NCT03383978)
  • 15 Mar 2017 NantKwest plans a phase I trial of HER2.taNK for Solid tumours in USA in the second half of 2017
  • 15 Mar 2017 NantKwest announces intention to submit IND to US FDA for HER2.taNK for Solid tumours by mid-2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top